CONNECTA is a clinical stage biotechnology company committed to developing new treatments for central nervous system (CNS) disorders without treatment options, and helping to improve the quality of life of patients and families.

The company was founded in July 2019 as a spin-off of Prous Institute Biomedical Research, a private research organization based in Barcelona.

In September 2020, we completed a seed round led by the founders, Inveready, one of the leading early-stage venture capital companies in Spain, and CDTI Innvierte, the General State Administration body supporting knowledge-based innovation.